Education
About Us
Working with TipRanks
Follow Us
Daxor Corp (DXR)
NASDAQ:DXR
DXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.55 - $10.00
Previous CloseN/A
Volume734.00
Average Volume (3M)8.44K
Market Cap
$35.03M
Enterprise Value$46.66M
Total Cash (Recent Filing)$57.74K
Total Debt (Recent Filing)$27.39M
Price to Earnings (P/E)79.2
Beta0.19
Next Earnings
Aug 21, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jan 05, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding4,836,930
10 Day Avg. Volume4,784
30 Day Avg. Volume8,441
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)N/A
Price to Sales (P/S)261.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.90
Enterprise Value/Ebitda-14.73
Forecast
1Y Price Target
$23.50Price Target Upside191.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Daxor News
PremiumCompany Announcements
Daxor Corporation Reports Robust Growth in Earnings Call
PremiumCompany Announcements
Daxor Corporation Reports Strong 2024 Financial Growth
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentDaxor is developing a next-generation BVA that is more than three times faster and capable of providing full results at the bedside, with FDA approval expected in 2025.
Regulatory StrategyThe decision to pivot to a single 510(k) submission, rather than a dual CLIA waiver approach, is a prudent regulatory strategy that reduces data burden and accelerates the approval timeline.
Revenue GrowthThe company reported strong revenue growth of +117% in its blood volume business across leading medical centers in the U.S.
Bears Say
Financial ClassificationDaxor’s engagement with the SEC to transition from its current investment company classification to an operating company, which should improve financial transparency, attract a broader investor base, and potentially lead to increased trading volume.
Future Device SalesThe company's outreach to healthcare providers continues to drive greater awareness of its technology’s benefits, contributing to achieving cash flow breakeven in the first two months of 2025 despite no sales yet from its next-generation BVA device.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.55% Insiders
1.02% Mutual Funds
0.31% Other Institutional Investors
92.11% Public Companies and
Individual Investors
DXR FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was $6.55 and its highest was $10.00 in the past 12 months.
What is Daxor Corp’s market cap?
Daxor Corp’s market cap is $35.03M.
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Aug 21, 2025 which is in 130 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Mar 06, 2025. The company reported $0.439 earnings per share for the quarter, beating the consensus estimate of N/A by $0.439.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp pays a Notavailable dividend of $0.029 which represents an annual dividend yield of N/A. See more information on Daxor Corp dividends here
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 4,836,930 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of $0.439 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.96%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DXR
---
Daxor Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (191.93% Upside)
$23.50 (191.93% Upside)
Insider Transactions
Bought Shares
Worth $63.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.58%
12-Months-Change
Fundamentals
Return on Equity
1.54%
Trailing 12-Months
Asset Growth
5.06%
Trailing 12-Months
Company Description
Daxor Corp
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
---
DXR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a robust performance with significant revenue growth, successful strategic acquisitions, and expanded clinical partnerships. Despite a delay in FDA approval and a decrease in unrealized appreciation, the company showcased strong momentum and promising developments for the future.Read More>---
DXR Stock 12 Month Forecast
Average Price Target
$23.50
▲(191.93% Upside)
Technical Analysis
Best Analysts Covering DXR
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-3.52%
reiterated a buy rating last month
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -3.52% per trade.
---